PDCD1 and skin squamous cell carcinoma: A retrospective analysis of 13 patients with head and neck cSCC and cPNI treated with anti–PD-1 therapy reported an objective response rate of 69.2% (46.2% complete response and 23.1% partial response) (Table 1) [21].